Voyageur Pharmaceuticals Ltd.
VYYRF
$0.10
$0.0110.23%
OTC PK
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 94.18% | 237.10% | -28.71% | 115.66% | 78.61% |
| Depreciation & Amortization | -33.33% | -33.33% | -33.33% | -33.33% | -25.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 93.50% | 241.15% | -28.71% | 115.46% | 78.36% |
| Operating Income | -93.37% | -237.66% | 28.71% | -115.46% | -78.36% |
| Income Before Tax | -86.11% | -262.78% | 6.11% | -133.37% | -61.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -86.11% | -262.78% | 6.11% | -133.37% | -61.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.11% | -262.78% | 6.11% | -133.37% | -61.17% |
| EBIT | -93.37% | -237.66% | 28.71% | -115.46% | -78.36% |
| EBITDA | -93.50% | -238.02% | 28.71% | -115.66% | -78.61% |
| EPS Basic | -45.83% | -200.00% | 20.00% | -105.56% | -50.00% |
| Normalized Basic EPS | -46.67% | -200.00% | 21.05% | -91.67% | -87.50% |
| EPS Diluted | -45.83% | -200.00% | 20.00% | -105.56% | -50.00% |
| Normalized Diluted EPS | -46.67% | -200.00% | 21.05% | -91.67% | -87.50% |
| Average Basic Shares Outstanding | 27.96% | 20.08% | 16.05% | 17.16% | 5.05% |
| Average Diluted Shares Outstanding | 27.96% | 20.08% | 16.05% | 17.16% | 5.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |